INDIANA, Pa.--(BUSINESS WIRE)--Clinical research company Antria, Inc. today announced that the United States Food and Drug Administration (FDA) has approved the next step in medical research to help patients look younger using their own stem cells.
“ADSCs are one of most promising avenues of medical research to use the stem cells of patients to create a more natural, longer-lasting youthful look than traditional cosmetic surgery”
Antria is the first company to gain FDA approval to initiate Phase 2 clinical trials with autologous adipose derived stem cells (ADSC) for plastic surgery. Antria completed the first phase of research in May 2014, which showed promising results.
“ADSCs are one of most promising avenues of medical research to use the stem cells of patients to create a more natural, longer-lasting youthful look than traditional cosmetic surgery,” said Dr. Leonard Maliver, chief executive officer of Antria. “The medical benefits of Antria’s research on ADSCs are not limited to cosmetic surgery. We believe we can apply our research on ADSCs to improve a wide range of medical conditions, including wound and fracture healing, congestive heart failure, and forms of arthritis.”
Antria’s patent-pending process uses liposuction to extract the patient’s own fat. Within one hour, stem cells are prepared from that material. Clinicians then inject the stems cells under the patient’s facial skin to reduce the appearance of wrinkles, scars and sagging skin.
Unlike other methods, the Antria process does not include artificial dermal fillers and non-augmented fat grafts. By combining fat grafting with a patient’s own stem cells, Antria’s process hopes to create a more natural appearance, which lasts longer. One of the critical components of Antria’s process to isolate stem cells from adult fat cells is its proprietary product AdipolyxTM, a collegenase-based reagent. AdipolyxTM has potential applications to help patients suffering from arthritis, wound healing, ischemic limbs, multiple sclerosis, impotence, and urinary incontinence. Antria expects its next clinical trial to use ADSCs for breast augmentation procedures.
In Phase 2, Antria will expand the clinical trial to include a much larger group of participants. Antria will begin Phase 2 trials in Gainesville, Florida within the next 90 days.
About Antria
Antria is a clinical research organization that focuses on the discovery and development of new products and treatments with stem cells derived from adult patients’ own fat cells, known as autologous derived stem cells (ADSCs) to help patients with various chronic and acute medical conditions. Founded in 2010, Antria is based in Indiana, Pennsylvania with additional offices in Gainesville, Florida.
Dr. Leonard Maliver, chief executive officer
Dr. Maliver graduated medical school from Thomas Jefferson Medical School and later completed his urological residency program at Einstein-Montefiore Medical Center in Bronx, New York. Currently, he is an active staff member and board-certified urologist at Indiana Regional Medical Center.
Dr. Shah Rahimian, president of research and development
Dr. Rahimian graduated medical school from the University of Istanbul in 2000 where he subsequently pursued and later received his doctorate of philosophy in public health. In the last 10 years, Rahimian has served as a senior scientist and general surgeon at Istanbul University, vice president and director of clinical research at Ilumina Clinical Associates, and a consultant for the biomedical industry throughout North America, Asia, and Europe.
Contacts
Antria, Inc.
Sarah Boyer, 724-349-0520
sboyer@antria.org
Help employers find you! Check out all the jobs and post your resume.
